Firm patent wall of ‘Nexavar,’ a liver cancer treatment, to overcome for domestic companies
The challenges of domestic pharmaceutical companies to nullify the period extension of the substance patent of ‘Nexavar(sorafenib tosilate, Bayer),’ a liver cancer targeted treatment, have encountered difficulties.
According to the industry concerned on the 6th, Huons, a domestic medium-sized co...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
